Intravenous Labetalol and Intravenous Diazoxide in Severe Hypertension Complicating Pregnancy
- 1 February 1986
- journal article
- clinical trial
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 26 (1) , 26-29
- https://doi.org/10.1111/j.1479-828x.1986.tb01523.x
Abstract
The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented. Both drugs had an efficient hypotensive action. The reduction in blood pressure in the labetalol group was better controlled and this may be a factor influencing perinatal outcome. Because of the freedom of maternal and fetal side-effects, labetalol given by intravenous infusion is a more appropriate drug for use in the management of hypertensive crises occurring in pregnancy and labour.Keywords
This publication has 6 references indexed in Scilit:
- Hydralazine — is there a safe dose?The Medical Journal of Australia, 1985
- The lupus syndrome induced by hydralazine: a common complication with low dose treatment.BMJ, 1984
- Comparison of the Alpha and Beta Blocking Drug, Labetalol, and Methyl Dopa in the Treatment of Moderate and Severe Pregnancy-Induced HypertensionClinical and Experimental Hypertension, 1980
- Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension.Published by Wiley ,1979
- Use of labetalol in the treatment of severe hypertension during pregnancy.British Journal of Clinical Pharmacology, 1979
- Intravenous Diazoxide in the Treatment of Severe Pre-Eclamptic Toxaemia and EclampsiaAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1973